Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
RANCHO CORDOVA, Calif., May 04, 2017 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the company will report its financial results for the fiscal third quarter ended March 31, 2017, after the market closes on Thursday, May 11, 2017. A conference call and audio webcast will follow at 4:30 p.m. EDT (1:30 p.m. PDT).
Participants may access the call by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing “Cesca.” To access a live webcast of the call, please visit: http://services.choruscall.com/links/kool170515.html
A replay of the call can be accessed approximately one hour after completion of the call and will be available until June 12, 2017. To listen to the replay, dial 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and reference access code 10105884.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
Cesca is an affiliate of the BoyaLife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc. [email protected] Investor Contact: Rx Communications Paula Schwartz 917-322-2216 [email protected]
